Human Antibodies & Hybridomas

7-9 November 2012, Buena Vista Palace Hotel, Orlando, Florida, USA

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Friday 9th November

SESSION 9:
MAB PRODUCTION & DSP ISSUES

Moderator: David Humphreys (UCB Pharma, Slough, Berkshire, UK)

09.00-09.30
‘Investigating the use of chromatin structure modifying elements to increase antibody expression and clone stability in CHO-K1 cells’
Kerry Tyson (UCB Pharma, Slough, Berkshire, UK)

09.30-09.50
‘Development of recombinant antibody mixtures for targeting of multiple epitopes’
Torben P. Frandsen (Symphogen A/S, Lyngby, Denmark)

09.50-10.10
‘Developing the next generation designer cell lines as a customized approach for optimized therapeutic protein production’
Pierre-Alain Girod (Selexis, Geneva, Switzerland)

10.10-10.30
‘Selections with cells and membranes using a yeast-based IgG discovery platform enables isolation and successful optimization of human antibodies against integral membrane proteins’
Jerry Thomas (Adimab LLC, Lebanon, New Hampshire, USA)

10.30-11.00
‘High throughput generation of antibodies to novel, modified and difficult targets’
Stefan Dubel (Technische Universitat Braunschweig, Braunschweig, Germany)

11.00-11.15
Coffee Break

SESSION 10:
PRE-CLINICAL

Moderator: Torben P. Frandsen (Symphogen A/S, Lyngby, Denmark)

11.15-11.45
‘CASE STUDY: Moving Pritumumab from a hybridoma to a CHO expression system’
Gregory T. Bleck (Catalent Biologics, Middleton, Wisconsin, USA)

11.45-12.05
‘Comparability and characterization of fully human IgM antibodies’
Michael Rudolf (Kenta Biotech, Zurich, Switzerland)

12.05-12.25
‘Humanization and cell development for Clinical Studies: A case study’
Richard Buick (Fusion Antibodies Ltd, Belfast, Northern Ireland)

12.25-12.45
‘Preclinical efficacy and safety of Probody™ therapeutics’
Henry B. Lowman (CytomX Therapeutics Inc., South San Francisco, California, USA)

12.45-13.05
‘Augmented clearance of botulinum neurotoxin using a bispecific ‘heteropolymer’ antibody specific for complement receptor type 1 (CR1) on RBC’s’
Sharad P. Adekar, Ahmed Syed Ubaid, Andrew T. Segan, Ramadevudu Puligedda, Margaret A. Lindorfer, Cindy Chen, Rodney Bermudez, Sarang Puranik, Lance L. Simpson, Ronald P. Taylor and Scott K. Dessain (Immunome Inc., Wynnewood, Pennsylvania, USA)

13.05-14.00
Lunch Break

SESSION 11:
LATE-BREAKER PRESENTATIONS

Moderator: Mark C. Glassy (IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA)

14.00-14.20
‘Manufacture of recombinant IgM-antibodies – A case study’
H. Katinger, K. Fauland, R. Weik, M. Barut, S. Peljhan, A. Strancar and M. Zorz (Polymun Scientific GmbH, Klosterneuberg, Austria)

14.20-14.40
‘A novel antigen specific immunoglobulin expressing cell lineage in immune animals distinct from classical B cell populations’
Jody Berry (BD Biosciences, La Jolla, California, USA)

14.40-15.00
‘Human primary B lymphocytes for the rapid hign throughput discovery of native therapeutic monoclonal antibodies’
Majid Mehtali (Vivalis,Saint-Herblain, Nantes, France)

15.00-15.20
‘Synthetic human antibodies targeting staphylococcal enterotoxin B (SEB) for prophylaxis and treatment of toxic shock syndrome’
Gang Chen, Hatice Karauzum, Laura Abaandou, Mahta Mahmoudieh, Atefeh R. Boroun, Sergey Shulenin, V. Sathya Devi, Eric Stavale, Kelly L. Warfield, Larry Zeitlin, Chad J. Roy, M. Javad Aman and Sachdev S. Sidhu (University of Toronto, Toronto, Canada)

15.20-15.40
‘Biological features of human catalytic antibody light chains showing suppressive effect on influenza virus infection’
Naoko Fujimoto, Emi Hifumi and Taizo Uda (Oita University, Oita-shi, Japan)

SESSION 12:
CLOSING PLENARY

Moderator: Mark C. Glassy (IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA)

15.40-16.10
‘Human antibodies – where are we at and where are we going? – including summary of HAH 2012 conference’
J. Donald Capra (OMRF, Oklahoma City, Oklahoma, USA)

16.10-16.15
Closing Remarks & Departure

* This final programme is correct at the time of publishing. However the organisers reserve the right to make any alterations that may be required in the interests and integrity of the final conference programme.

 

HAH 2012 Delegates

Login details will be supplied after you have registered for the event.


HAH 2012 Sponsors

  • Affimed
  • Arsanis Biosciences
  • Symphogen
  • Geneuro
  • Theraclone Sciences
  • Selexis
  • UCB Celltech
  • Immunome
  • Catalent
  • Kadmon
  • Intercell
  • GlaxoSmithKline
  • ImmunoGen
  • OMT
  • Mapp Biopharmaceutical
  • Adimab
  • Nascent Biologics
  • Novartis Vaccines
  • Kenta Biotech
  • Retroscreen Virology
  • Genentech
  • Aldevron
  • Regeneron
  • ImClone Systems
  • Morphosys
  • Becton Dickinson
  • Fenwick & West
  • ModiQuest
  • Morphotek
  • Fusion Antibodies
  • CytomX Therapeutics
  • Dyax

HAH 2012 Downloads

HAH 2012 Leaflet

HAH 2012 Mailing List

Name
E-mail Address
What is 1+4-2?